Download - Amir naiberg

Technology Transfer from the Weizmann Institute of ScienceYeda Research & Development Co. Ltd.

w w w . Y e d a R n D . c o m

Technology Transfer from the Weizmann Institute of ScienceTechnology Transfer from the Weizmann Institute of Science

f r o m o u r p i p e l i n e t o y o u r b o t t o m l i n ef r o m o u r p i p e l i n e t o y o u r b o t t o m l i n e

Amir Naiberg, CEOAmir Naiberg, CEO



The Weizmann Institute of Science Discovering Basic ScienceThe Weizmann Institute of Science Discovering Basic Science





Weizmann Institute of ScienceCuriosity Driven Research

Weizmann Institute of ScienceCuriosity Driven Research



What will be the next scientific revolution?

What will be the next scientific revolution?

Who will make the next scientific revolution?

Who will make the next scientific revolution?



The next scientific revolution will be• driven by scientists

who have a multidisciplinary view of science

• the opportunity to take risks

• the infrastructure to work

• the freedom to think



Mathematics

Computer Science

Chemistry Biology

Physics Biochemistry

The Weizmann Institute of ScienceThe Pool of knowledge



The Weizmann Institute of ScienceQuality Driven

Average number of citations per paper

Technion

TAU

HUJ

WIS

BGU

BIU

Haifa

“Best Place in Academia” ranked No.1 in 2011 among top International academic Institutions” TheScientist.com



ERC Starter+Established 2007-2010ERC Starter+Established 2007-2010

Weizmann

Technion Hebrew Tel Aviv Ben Gurion

Bar Ilan Haifa0

5

10

15

20

25

30

35

Su

cce

ss R

ate

(%

)



The Need to Rethink InnovationThe Need to Rethink Innovation

Sources: InnoThink Center For Research In Biomedical Innovation; Thomson Reuters Fundamentals via FactSet Research SystemsThe Truly Staggering Cost Of Inventing New Drugs, Matthew Herper (Forbes, 10.2.2012)

Number of Drugs Approved

R&D Spending Per Drug ($Mil)

Total R&D Spending 1997-2011 ($Mil)

Company

5 11,790.93 58,955 AstraZeneca

10 8,170.81 81,708 GlaxoSmithKline

8 7,909.26 63,274 Sanofi

11 7,803.77 85,841 Roche Holding AG

14 7,727.03 108,178 Pfizer Inc.

15 5,885.65 88,285 Johnson & Johnson

11 4,577.04 50,347 Eli Lilly & Co.

8 4,496.21 35,970 Abbott Laboratories

16 4,209.99 67,360 Merck & Co Inc

11 4,152.26 45,675 Bristol-Myers Squibb Co.

21 3,983.13 83,646 Novartis AG

9 3,692.14 33,229 Amgen Inc.

139 5,773 802,468 Total



Enhancing medical treatment efficacy using the most advanced research tools

The Israel National Center for Personalized MedicineThe Israel National Center for Personalized Medicine

BENCH TO BEDSIDE



Personalized Medicine – What is it?Personalized Medicine – What is it?



Sequencing UnitBuilding on the Weizmann Crown Human Genome Center, the unit will provide High Throughput DNA/RNA sequencing and affiliated bioinformatics to analyse genomic variations, transcriptomes, non-coding RNAs, and editomes.

The Israel National Center for Personalized MedicineInfrastructure

The Israel National Center for Personalized MedicineInfrastructure

Proteomics UnitArising from the Weizmann Advanced Mass Spectrometry Lab, the unit will provide quantitative proteomics analyses to study differential expression and post-translational modifications of proteins.

Bioinformatics UnitBuild on the Bioinformatics and Biological Computing Group at Weizmann, the unit will use advanced tools to identify promising gene targets, key proteins andcritical pathways.

Small Molecules Screening UnitIncorporating the Weizmann Structural Proteomics Unit for protein production and structure determination capacities, the unit will screen small molecule and siRNA libraries for desired biological effects.



Yeda Research & Development Co. Ltd. Yeda Research & Development Co. Ltd. Bridging Research & DevelopmentBridging Research & Development





Yeda = KnowledgeYeda = Knowledge

Basic

Bottom upCuriosity drivenPublish or Perish

Long termAvoid commercial

risks

Applied

Top DownDemand driven

SecrecyShort termRisk taking



Yeda Research & Development Co. Ltd. Yeda Research & Development Co. Ltd. A World Leader in Technology TransferA World Leader in Technology Transfer

Dozens of “Weizmann-Inside” products on the market.

Total annual royalty-generating sales in 2011:Over $15 Billion.

Over 50 new companies were established around Yeda’s technologies.

Yeda owns the largest portfolio of patents in Israel:560 live patent families, with more than 1,700 patent families filed since 1971.

Dozens of “Weizmann-Inside” products on the market.

Total annual royalty-generating sales in 2011:Over $15 Billion.

Over 50 new companies were established around Yeda’s technologies.

Yeda owns the largest portfolio of patents in Israel:560 live patent families, with more than 1,700 patent families filed since 1971.



Inte

lIB

MTe

va

Applie

d m

ater

ials

Yeda

SanD

isk

Yiss

um HP

Cisco

Ramot

Refae

l

Mar

vel

Tech

nion

Texa

snst

rum

ents

Ishc

ar

Cifon

0

50

100

150

200

250

300

350

400

450403

325

164144 141

95 90 87 77 77 63 62 61 61 57 57

Source: BDI

Israeli Patents in the USA (Accumulated for the Years 2006-2010)



Governmental SupportGovernmental Support



Innovation Capacity ScoreInnovation Capacity Score

Enterprise Support encourages growth of domestic biotechnology startups and lures foreign companies to establish facilities domestically.

Source: SCEINTIFIC AMERICAN/WORLDVIEW 2010



Intervention Programs Intervention Programs

KAMIN85%

90%

60%

60%



Financial support for academic, basic research. Public support is essential for academic freedom.

Intervention programs for “bridging the gap”.

Legal infrastructure: intellectual property rights (IPR) laws, Taxations, corporate law, etc.

Fixing market failures.

Financial support for academic, basic research. Public support is essential for academic freedom.

Intervention programs for “bridging the gap”.

Legal infrastructure: intellectual property rights (IPR) laws, Taxations, corporate law, etc.

Fixing market failures.

The Role of GovernmentsThe Role of Governments



Global vs. LocalGlobal vs. Local

Science is inherently global: it is like parachute, it only functions when open; Scientists look for the international collaborators which most fit their research needs.

Industry aims at global markets; it looks for the best international deals.

Governments act Locally – for national growth, for the local industry, for jobs creation, etc.

=> Government involvement is against internationalization of R&D.

Science is inherently global: it is like parachute, it only functions when open; Scientists look for the international collaborators which most fit their research needs.

Industry aims at global markets; it looks for the best international deals.

Governments act Locally – for national growth, for the local industry, for jobs creation, etc.

=> Government involvement is against internationalization of R&D.



Government’s involvement in university-industry relations Government’s involvement in university-industry relations

Under the responsibility of the office of the Chief Scientist at the ministry of Industry, Trade and Labor (OCS).

Different intervention programs for university-LOCAL industry collaboration.

Restrictions on exporting of knowledge created under these programs.

Under the responsibility of the office of the Chief Scientist at the ministry of Industry, Trade and Labor (OCS).

Different intervention programs for university-LOCAL industry collaboration.

Restrictions on exporting of knowledge created under these programs.



SummarySummary

Israel’s example has shown that successful global TT can go together with excellent science and bring products to the marketplace.

Acting globally scientifically and the freedom of operation of the TTOs’ were essential for this success and brought investments to Israel.

Lately, government’s policy is more dominant, trying to encourage LOCAL TT.

EU, as a superstructure, should support cross border technology transfer.

Israel’s example has shown that successful global TT can go together with excellent science and bring products to the marketplace.

Acting globally scientifically and the freedom of operation of the TTOs’ were essential for this success and brought investments to Israel.

Lately, government’s policy is more dominant, trying to encourage LOCAL TT.

EU, as a superstructure, should support cross border technology transfer.



www. YedaRnD. c o mT h a n k y o u